MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

23.14 5.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.91

Максимум

23.25

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+63.82% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	105M 2.3B
Предишно отваряне	17.28
Предишно затваряне	23.14

Настроения в новините

By Acuity

42%

58%

132 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2026 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14.04.2026 г., 23:24 ч. UTC

Горещи акции

Stocks to Watch: Gloo, Broadcom, GitLab

14.04.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14.04.2026 г., 21:32 ч. UTC

Значими двигатели на пазара

GitLab Shares Rise on Expanded Google Cloud Collaboration

14.04.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14.04.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14.04.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14.04.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14.04.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

14.04.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 20:32 ч. UTC

Горещи акции

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14.04.2026 г., 19:59 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 19:38 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14.04.2026 г., 19:09 ч. UTC

Придобивния, сливания и поглъщания

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

63.82% нагоре

12-месечна прогноза

Среден 34.96 USD 63.82%

Висок 47 USD

Нисък 21.8 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

132 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.